Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

A Prospective, Multicenter, Randomized Controlled Trial Investigating the Impact of Fasting Duration on Postoperative Rebleeding Following Esophageal Variceal Ligation.

NCT07774143 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2026-06-20
Last updated
2026-08-19

Condition(s) studied

Esophageal Varices

Investigational drug(s) / intervention(s)

fasting periods of 24 hoursfasting periods of 48 hoursfasting periods of 6 hours

fasting periods of 24 hours: Post-balloon occlusion procedure: fasting for 24 hours

fasting periods of 48 hours: Post-balloon occlusion procedure: fasting for 48 hours

fasting periods of 6 hours: Post-balloon occlusion procedure: fasting for 6 hours

Study summary

To evaluate the efficacy and safety of early postoperative oral intake (with a fasting period of 6 hours) versus delayed postoperative oral intake (with fasting periods of 24 hours or 48 hours) in patients with cirrhosis undergoing esophageal variceal ligation therapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: -1. The patient must be aged\>18 years; 2. The diagnosis of portal hypertension must be confirmed, with gastroscopy revealing severe esophageal varices and a positive red sign; 3. For patients undergoing endoscopic variceal ligation (EVL) due to esophageal varices (including those with hemorrhage or those eligible for elective ligation), successful intraoperative ligation is achieved (achieving hemostasis or completing the predetermined ligation procedure). 4\. Sign the informed consent form Exclusion Criteria: * 1\. Uncontrolled active bleeding or concurrent bleeding from gastric fundal varices; 2.History of prior TIPS, EVL, or surgical shunt procedures; 3. Presence of severe systemic diseases, such as sepsis, uremia, or advanced hepatocellular carcinoma (HCC); 4.Mechanical ventilation with retained catheter, inability to take oral intake, or significant dysphagia, or a history of major esophageal/gastric surgery that has impaired swallowing function; 5. Severe hepatic failure: Child-Pugh score\>13; profound jaundice (serum bilirubin\>10 mg/dL) accompanied by altered consciousness beyond Stage II or massive ascites; 6.Pregnancy or lactation; 7. Inability to provide informed consent.

Primary outcome measure(s)

  • Rate of early postoperative rebleeding — Week 0-6

Trial sites (12)

FacilityCityRegionStatus
The Fifth People's Hospital of Anyang Anyang China Recruiting
The Secend People's Hospital of Jiaozuo Jiaozuo China Recruiting
Huaihe Hospital of Henan University Kaifeng China Recruiting
Luohe Central Hospital Luohe China Recruiting
Luoyang Central Hospital Luoyang China Recruiting
Nanyang Central Hospital Nanyang China Recruiting
Sanmenxia Central Hospital Sanmenxia China Recruiting
Shangqiu Municipal Hospital Shangqiu China Recruiting
The First Affiliated Hospital of Xinxiang Medical University Xinxiang China Recruiting
Xuchang Central Hospital Xuchang China Recruiting
the First Affiliated Hospital of Zhengzhou University Zhengzhou China Recruiting
Zhoukou Central Hospital Zhoukou China Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07774143 on ClinicalTrials.gov ↗ ← All trials in China